The FDA has granted “breakthrough” status to a generative artificial intelligence chatbot designed for surgical patients recovering from surgery. This decision may serve as a guide for the agency's regulation of generative AI tools. The chatbot is designed to support patients in the postoperative period. The FDA's decision signals a planned approach to regulating such AI tools. No other specific details about functionality or study results are provided in the article.